ClinicalTrials.gg
CompletedNCT07219368Updated Nov 12, 2026

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

A Phase 1 interventional study of MT-201 and Placebo in Healthy Volunteer, sponsored by Mirador Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Mirador Therapeutics, Inc. · Phase 1, Interventional, and Other

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • MT-201
  • Phase 1
03

In context

Lead sponsor

Mirador Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male participant or female participant of nonchildbearing potential between 19 and 55 years of age (inclusive) at the time of signing .
  2. Female participants must be of nonchildbearing potential, defined as or surgically sterile, and have official documentation, at least 6 months prior to the first dose.
  3. Male participants with female partners of who are involved in heterosexual intercourse or activities that could lead to pregnancy must use barrier method of (male condom) and refrain from sperm donation.
  4. Good general health.
  5. Able to provide written informed consent and understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of any organ system disease.
  2. Abnormal laboratory assessments, physical exam of outside the normal range that is judged by the Investigator to be clinically significant.
  3. History of alcohol or drug abuse within the past 24 months.
  4. Current use or history of regular tobacco, or nicotine-containing products within 3 months prior to screening.
  5. Administration or use of any drug or device within 30 days preceding the first dose of study drug administration.
  6. Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose of MT-201

    To assess the safety and tolerability of single intravenous/subcutaneous doses of MT-201

    Drug: MT-201

  • Experimental
    Multiple Ascending Dose of MT-201

    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of MT-201

    Drug: MT-201

  • Placebo comparator
    Single Ascending Dose Placebo Arm

    To assess the safety and tolerability of single intravenous/subcutaneous doses of placebo

    Drug: Placebo

  • Placebo comparator
    Multiple Ascending Dose Placebo

    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of placebo

    Drug: Placebo

Interventions

  • DrugMT-201

    MT-201

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants with non-SAEs and SAES

    Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.

    Time frame: Up to 40 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Oct 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 21, 2025
StartActual
Oct 8, 2025
Primary completionActual
Oct 20, 2026was Nov 2026
CompletionActual
Oct 20, 2026was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Nov 24, 2026→Oct 20, 2026 (actual)
Nov 12, 2026
Study completion
Dec 31, 2026→Oct 20, 2026 (actual)
Nov 12, 2026
Enrollment
72 (estimated)→56 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Nov 24, 2026→Oct 20, 2026 (now actual)
    Study completion Dec 31, 2026→Oct 20, 2026 (now actual)
    Enrollment 72 (estimated)→56 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07219368
Lead sponsor
Mirador Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Oct 8, 2025
Primary completion
Oct 20, 2026
Completion
Oct 20, 2026
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adecatumumab

Start the discussion